ASCO GI 2024: ctDNA as a Predictive Biomarker for Patients With Colon Cancer
Posted: 02/14/2024 | By: Melissa E. Fryman, MS

A study presented by Morris et al at the 2024 ASCO Gastrointestinal Cancers Symposium investigated if positive ctDNA status after resection may identify patients with colon cancer who will benefit from adjuvant chemotherapy (Abstract 5).

Question 1 of 5

Patients enrolled into this prospective phase II/III clinical trial met all of the following inclusion criteria, except:

Choose 1